New article in JAMA Network Open!
PharmaSafe researchers set out to answer the question "Is prenatal exposure to triptans associated with an increased risk of attention-deficit/hyperactivity disorder (ADHD) in offspring?".
By using the MoBa birth cohort including 10,167 children with ADHD, we found no associations between prenatal exposure to triptans and ADHD diagnosis or ADHD symptoms among offspring. These findings suggest that there is no increased risk of ADHD in offspring associated with prenatal exposure to triptans.
Read the full article here: 10.1001/jamanetworkopen.2022.15333.